Alpha IVF Group Bhd (KL:ALPHA) reported a notable 23.6% increase in its net profit for the second quarter ending November 30, 2024 (2QFY2025), reaching RM15.1 million compared to RM12.21 million in the same period last year. This growth was fueled by higher sales revenue generated from foreign patients.
The company’s revenue for the quarter rose by 12.2% year-on-year to RM43.24 million, up from RM38.54 million in 2QFY2024, as per its filing on the stock exchange. Despite the strong financial performance, no dividend was declared for this quarter.
A significant factor in Alpha IVF’s growth was the increase in foreign patient contributions to its Malaysian operations, which surged to 71.2% of total revenue, up from 57.2% in the same quarter of 2024. The bulk of this growth came from patients in Indonesia and China.
Indonesian patients remain Alpha IVF’s largest customer base, contributing 34.9% of total revenue, while Chinese patients accounted for 25.2%. The company highlighted the rapid expansion of its Chinese clientele, with revenue from this segment increasing fourfold to RM8.1 million compared to the previous year.
For the first half of FY2024, Alpha IVF’s net profit grew 16.4% year-on-year to RM29.48 million from RM25.34 million. Revenue during the same period rose by 7.6% to RM86.24 million, up from RM80.14 million.
The company reported that domestic operations in Malaysia accounted for RM38 million, or 87.8%, of its 2QFY2025 revenue, with the remainder stemming from its operations in Singapore.
Alpha IVF’s Group Managing Director, Datuk Dr. Colin Lee Soon Soo, shared that the company will continue to drive its market expansion efforts throughout FY2025, capitalizing on recent regional successes. “In addition to China, we are expanding our footprint in Southeast Asia, with a full-fledged IVF center in the Philippines and a satellite clinic in Indonesia, aiming to tap into these rapidly growing markets,” Lee said.
He also expressed confidence in the company’s future growth prospects, stating that the expansion of services in both existing and new markets positions Alpha IVF well for further strengthening its local and regional presence.
As part of its strategy, Alpha IVF recently opened a new sales office in Guangzhou, its second office in China, following the successful launch of its first sales office in Shanghai last September.
Alpha IVF’s shares closed steady at 32.5 sen on Tuesday, giving the company a market capitalization of RM1.58 billion.
Related topics:
Endometriosis Identified as a Major Cause of Hospitalization in Australia, Study Finds
Does Birth Control Cause Fibroids?
Astronaut Kellie Gerardi Responds to Criticism Over Fertility Struggles
